Drug intelligence / Profile preview

br01t

Development stage: Unknown
Lead developer: Brise Pharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Parenteral

Overview

BR01T is a recombinant humanized monoclonal antibody developed by Brise Pharmaceuticals for the treatment of chronic low back pain (CLBP). It acts as an antagonist of tropomyosin receptor kinase A (TrkA), selectively inhibiting this target to provide pain relief in both acute and chronic painful states. Unlike traditional opioids or nonsteroidal anti-inflammatory drugs (NSAIDs), BR01T’s mechanism offers optimal analgesia without bone-related side effects such as bone damage. The drug is currently being evaluated in a Phase I clinical trial to assess its safety and tolerability in patients with CLBP[1][2][4][6][8].

Targets

NTRK1 (Tropomyosin-related receptor kinase A)

Beyond the preview

Go deeper on br01t.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on br01t.

Explore the full profile